Advances in medical sciences · 2025
Mesothelin as a diagnostic biomarker in endometriosis: A cross-sectional study.
СтатьяМногоцентровое исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kiecka Kamil, Zygula Aleksandra, Sankiewicz Anna, Kuzmicki Mariusz, Lawicki Slawomir, Ciebiera Michal, Issat Tadeusz, Blaszczyk Jan, Cendrowski Krzysztof, Gorodkiewicz Ewa, Laudanski Piotr
Аннотация
PURPOSE: Endometriosis is a prevalent gynecological condition often requiring invasive procedures for diagnosis. This study aimed to assess mesothelin (MSLN) as a potential non-invasive biomarker by analyzing its levels in peritoneal fluid (PF) and plasma.
MATERIALS/METHODS: In a multicenter cross-sectional study, MSLN concentrations were measured using Surface Plasmon Resonance imaging (SPRi) biosensors in samples from women undergoing laparoscopy for pelvic pain or infertility.
RESULTS: Significantly higher MSLN levels were observed in the PF of patients with endometriosis compared to controls (mean concentrations: 10.24 vs. 9.39 ng/mL, p = 0.038). The elevation was particularly notable in patients with stage I and II endometriosis compared to the control group (mean concentrations: 10.83 vs. 9.39 ng/mL, p = 0.049). No significant differences were observed in plasma.
CONCLUSIONS: Mesothelin in PF may be considered as a potential biomarker for endometriosis, especially in its early stages. Further studies are needed to confirm its diagnostic value.
MATERIALS/METHODS: In a multicenter cross-sectional study, MSLN concentrations were measured using Surface Plasmon Resonance imaging (SPRi) biosensors in samples from women undergoing laparoscopy for pelvic pain or infertility.
RESULTS: Significantly higher MSLN levels were observed in the PF of patients with endometriosis compared to controls (mean concentrations: 10.24 vs. 9.39 ng/mL, p = 0.038). The elevation was particularly notable in patients with stage I and II endometriosis compared to the control group (mean concentrations: 10.83 vs. 9.39 ng/mL, p = 0.049). No significant differences were observed in plasma.
CONCLUSIONS: Mesothelin in PF may be considered as a potential biomarker for endometriosis, especially in its early stages. Further studies are needed to confirm its diagnostic value.